کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8737646 | 1591368 | 2018 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ABOiNon-HLA antibodiesMPGNFCXMABO incompatibleMFIFSGSAT1RAMRAECA - Aecaantibody mediated rejection - آنتی بادی مهار شده ردAnti-endothelial cell antibodies - آنتیبادی های ضد اندوتلیالangiotensin II type 1 receptor - آنژیوتانسین II نوع 1 گیرندهflow cytometric crossmatch - جابه جایی سیاتومتر جریانmean fluorescent intensity - میانگین شدت فلورسنتFocal segmental glomerulosclerosis - گلومرول اسکلروز بخش مرکزی فوکوسmembranoproliferative glomerulonephritis - گلومرولونفریت غشایی غشایی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Retrospective studies of angiotensin II type 1 receptor antibodies (AT1R-Ab) and anti-endothelial cell antibodies (AECA) have linked these antibodies to allograft injury. Because rising healthcare costs dictate judicious use of laboratory testing, we sought to define characteristics of kidney transplant recipients who may benefit from screening for non-HLA antibodies. Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, were evaluated for AT1R-Ab and AECA. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff' 2009-2013 criteria. AT1R-Ab and AECA were detected using ELISA and endothelial cell crossmatches, respectively. AT1R-Ab levels were higher in patients who were positive for AECAs. Re-transplanted patients (pâ¯<â¯0.0001), males (pâ¯=â¯0.008) and those with FSGS (pâ¯=â¯0.04) and younger (pâ¯=â¯0.04) at time of transplantation were more likely to be positive for AT1R-Ab prior to transplantation. Recipients who were positive for AT1R-Ab prior to transplantation had increases in serum creatinine within 3â¯months post-transplantation (pâ¯<â¯0.0001) and developed abnormal biopsies earlier than did AT1R-Ab negative patients (126â¯days versus 368â¯days respectively; pâ¯=â¯0.02). Defining a clinical protocol to identify and preemptively treat patients at risk for acute rejection with detectable non-HLA antibodies is an important objective for the transplant community.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Human Immunology - Volume 79, Issue 4, April 2018, Pages 195-202
Journal: Human Immunology - Volume 79, Issue 4, April 2018, Pages 195-202
نویسندگان
Mary Carmelle Philogene, Sheng Zhou, Bonnie E. Lonze, Serena Bagnasco, Sami Alasfar, Robert A. Montgomery, Edward Kraus, Annette M. Jackson, Mary S. Leffell, Andrea A. Zachary,